Raltegravir and Abacavir/Lamivudine in Japanese Treatment-Naïve and Treatment-Experienced Patients with HIV Infection: a 48-Week Retrospective Pilot Analysis-Reference-Cited by-同舟云学术

Raltegravir and Abacavir/Lamivudine in Japanese Treatment-Naïve and Treatment-Experienced Patients with HIV Infection: a 48-Week Retrospective Pilot Analysis

Published:2016 Issue:1 Volume:69 Page:33-38
ISSN:1344-6304
Container-title:Japanese Journal of Infectious Diseases
language:en
Short-container-title:Jpn J Infect Dis

Author:

Suzuki Akihito¹,Uehara Yuki¹²,Saita Mizue¹,Inui Akihiro¹,Isonuma Hiroshi¹,Naito Toshio¹²

Affiliation:

1. Department of General Medicine, Juntendo University School of Medicine

2. Department of Infection Control Science, Juntendo University Faculty of Medicine

Publisher

Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Link

https://www.jstage.jst.go.jp/article/yoken/69/1/69_JJID.2014.236/_pdf

Reference16 articles.

1. 1. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568-79.

2. 2. Tanaka H, Akaza T, Juji T. Report of the Japanese Central Bone Marrow Data Center. Clin Transpl. 1996;139-44.

3. 3. Smith KY, Patel P, Fine D, et al. Randomized double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS. 2009;23:1547-56.

4. 4. Japanese Ministry of Health, Labour and Welfare. Guidelines for antiretroviral therapy. Available at <http://www.haart-support.jp/pdf/guideline2015.pdf>. Accessed September 28, 2015. Japanese.

5. 5. Nishijima T, Gatanaga H, Komatsu H, et al. Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection. PLoS One. 2012;7:e29977.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of abacavir/lamivudine with raltegravir in treatment-experienced and treatment-naïve patients with HIV-1 infection: an observational, retrospective, multi-centre study;International Journal of STD & AIDS;2019-01-10

2. Alternative switching strategies based on regimens with a low genetic barrier: do clinicians have a choice nowadays?;European Journal of Clinical Microbiology & Infectious Diseases;2018-11-15

3. Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study;PLOS ONE;2018-06-14

4. An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study;Infectious Diseases;2017-09-11

5. Multiple drugs;Reactions Weekly;2016-12